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Introduction
A thyroid nodule is defined by the American Thyroid 
Association (ATA) as “a discrete lesion within the thyroid 
gland that is radiologically distinct from the surrounding thyroid 
parenchyma” (1).
Thyroid nodules are very common in the general 
population, and their prevalence is dependent on the 
identification method used, with a high prevalence found in 
ultrasound (US) examination, ranging from 20% to 76% in 
the adult population (2). Non-palpable nodules detected on 
US or on other imaging examinations are called “thyroid 
incidentalomas” or “incidentally discovered nodules”. 
Thyroid nodules are more frequent in females, with an 
incidence 4 times higher in women than in men (3). This 
distribution can be explained by hormonal influences, as 
pregnancy is related with the increase in size and number 
of nodules (4). Thyroid nodules may determine gland 
dysfunction and compressive symptoms due to mass effect, 
but the main concern is to rule out their malignancy. 
A US exam is a safe, non-invasive, and fast imaging 
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technique: it is sufficiently sensitive for detecting thyroid 
nodules and identifying suspicious features and can be 
used to plan further investigation and management 
decisions (5,6).
Considering that the average prevalence of thyroid 
nodule malignancy is variable and ranges from 4.0% to 6.5% 
(7-9), the accurate estimation of the risk of malignancy on 
US could help identify those nodules with a high risk of 
cancer. Moreover, many fine-needle aspirations (FNAs) 
may also be obviated by identifying those nodules with an 
acceptably low incidence of malignancy (10).
Many inves t iga t ions  have  focused  on  the  US 
characteristics of thyroid nodules as indicators of nodule 
malignancy, and several US systems have been developed 
by an array of authors and institutions to stratify the nodule 
malignancy risk and provide a standardized language for 
radiologists and endocrinologists.
Here, we offer an overview of the most recent and 
recognized US classification systems for thyroid nodules 
including the differing proposals of the Thyroid Imaging 
Reporting and Data System (TI-RADS) (9,11-14) along 
with other guidelines from renowned endocrinological and 
radiological associations (15-17).
TI-RADS
Many studies have investigated the feasibility of applying 
the breast imaging reporting and data system (BI-RADS) 
concept to the US evaluation of thyroid nodules for the 
purpose of developing a TI-RADS.
In 2009, Horvath (11) was the first to propose TI-
RADS as a method to stratify the estimated risk of cancer 
in thyroid nodules and select those nodules needing to 
undergo FNA.
US features considered by this classification include 
echogenicity, microcalcifications, shape, irregular margins, 
peripheral halo, and presence of suspicious lymph nodes. 
TI-RADS includes 10 US patterns combined into categories 
with the increasing risk of malignancy and nodules classified 
as TI-RADS score 2 to 6 (11). 
The rationale of this classification system is that the 
risk of malignancy rises in parallel with the increase of 
the number of suspicious US features and with the lack of 
benign findings.
TI-RADS classification has been validated through a 
study on 502 nodules belonging to 210 patients conducted 
by the same Horvath (18) who demonstrated a TI-RADS 
sensitivity of 99.6% (95% CI: 98.9–100.0%), a specificity of 
74.35% (95% CI: 68.70–80.00%), a positive predictive value 
(PPV) of 82.1% (95% CI: 78.0–86.3%), and a negative 
predictive value (NPV) of 99.4% (95% CI: 98.3–100.0%) 
for malignancy. The estimated risk of malignancy was 0% 
in TI-RADS 2, 3.4% in TI-RADS 3, 10–80% in TI-RADS 
4, and 87% in TI-RADS 5. 
This system has been part of standardizing thyroid 
US examination reports and consolidating the disparate 
terminologies used by radiologists and endocrinologists all 
over the world. 
A modified version of TI-RADS that predicts malignancy 
risks only according to the number of suspicious US features 
was proposed by Kwak et al. in 2011 (9). These features 
include solid nodules, hypoechogenicity, microlobulated or 
irregular margins, microcalcifications or mixed calcification, 
and taller-than-wide shape.
The risk of malignancy increases as the number of 
suspicious US signs increases. According to this system, 
nodules with no suspicious US features have a 0.02–0.028 
fitted probability of malignancy, implying that it is 
safe to follow up with the lesion rather than perform a 
biopsy. Nodules in categories TI-RADS 4 or 5 with at 
least 1 suspicious US feature have more than 0.036 fitted 
probability of malignancy, indicating that a biopsy is 
warranted.
In a study including 167 nodules from 150 patients (19), 
the TI-RADS by Kwak et al. showed a sensitivity of 94%, 
a specificity of 28.2%, a PPV of 37.3%, and an NPV of 
91.2%; meanwhile, a study on 1,293 nodules (20) showed 
a sensitivity of 97.4%, a specificity of 29.3%, a PPV of 
23.3%, and an NPV of 98.1%. 
American College of Radiology (ACR)-TI-RADS
Another version of TI-RADS has been proposed by the 
ACR (12) in order to identify the most clinically significant 
malignancies and decrease the number of FNAs on benign 
nodules. 
This classification is not a pattern-based approach but is 
based on the assessment of different US features of thyroid 
nodules: composition, echogenicity, shape, margin, and 
echogenic foci; each of these features is associated with a 
score ranging from 0 to 3 points. 
The sum of the assigned points defines the risk of 
malignancies according to 5 grades, with each grade 
corresponding to benign, minimally suspicious, moderately 
suspicious, or highly suspicious for malignancy. This 
system does not include subcategories, nor a TR 0 group to 
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indicate the normal thyroid. 
Indications for FNA execution or US follow-up are based 
on ACR-TI-RADS level and on the maximum diameter 
of the nodules: for risk grades TR3–TR5, a size threshold 
at or above which FNA should be performed is indicated. 
Also, the lower size limits to perform follow-up US for 
TR3, TR4, and TR5 nodules were established in order 
to reduce the number of repeat examinations for nodules 
that are likely to be benign or not clinically significant. 
Highly suspect nodules are submitted to biopsy only if they 
are 1 cm or larger, while nodules that have a low risk for 
malignancy should be further investigated only when they 
measure 2.5 cm or more.
The main goal of ACR TI-RADS is to balance the 
benefit of detecting clinically significant malignancies 
against the risk and cost of submitting benign nodules 
or indolent and non-aggressive tumours to invasive 
investigations and treatment. The indications for US 
follow-up aim at reducing the eventuality that significant 
lesions remain undetected over time. 
In a study which included 1,112 thyroid nodules, 
this classification system had an area under the receiver 
operating characteristic curve (AUC) in discrimination of 
malignant nodules of 0.875 (21), while in another study on 
a series of 74 nodules from paediatric patients, the AUC 
was 0.75 (22). 
European (EU)-TI-RADS
European (EU)-TI-RADS is a classification system 
first proposed by Russ et al. in 2011 (23), and has been 
subsequently modified into an easier-to-use version, 
validated in a large prospective study in 2013 (24) and 
finally published as a European guideline in 2017 (13).
The latest version of EU-TI-RADS consists of five 
categories, each which is scored in correspondence to 
features from the US examination: EU-TI-RADS 1 refers 
to a US examination where no thyroid nodule is found, 
while the other 4 categories—nodules benign and with low, 
intermediate, and high risk—correspond in an increasing 
risk of malignancy.
EU-TI-RADS 2, with a risk of malignancy close to 0%, 
includes two patterns: pure/anechoic cysts and entirely 
spongiform nodules; these nodules should be considered 
as benign and FNA is not indicated. EU-TI-RADS 3, with 
a risk of malignancy around 2–4%, consists of nodules 
with oval shape, smooth margins, isoechoic or hyperechoic 
features, and a lack of any high-risk features; these nodules 
should be submitted to FNA only if >20 mm. EU TI-
RADS 3, with a risk of malignancy around 6–17%, consists 
of nodules with oval shape, smooth margins, mildly 
hypoechoic features, and a lack of any high-risk features; 
the evidence of a thin halo, cystic components, comet-
tail artefacts, peripheral vascularization, and low stiffness, 
lower the malignancy risk in this group, while the presence 
of discontinuous peripheral or rim macrocalcifications, a 
thick halo, predominantly central vascularization, and high 
stiffness, increase the  risk of malignancy; the threshold for 
FNA is 15 mm.
EU-TI-RADS 5 involves nodules presenting at least 1 
of the following high-risk signs: non-oval shape, irregular 
margins, microcalcifications, marked hypoechogenicity; the 
malignancy rate is 26–87% and nodules must be submitted 
to FNA when >1 cm.
In addition, the authors of EU-TI-RADS noted that 
extrathyroidal extension with disruption of the capsular 
margin increases the malignancy risk of a nodule and should 
be described in the report. On the other hand, hyperechoic 
spots associated with comet-tail artefacts, along with thin 
halo, are suggestive of benignity and reduce the suspicion of 
malignancy. 
This classification system also considers extra thyroid US 
features in stratifying the malignancy risk and the indication 
to FNA.
Notably, EU-TI-RADS accounts for suspicious 
lymphadenopathies: in case of a suspicious lymph node of 
thyroid origin, FNA of the lymph node itself and of the 
most suspicious thyroid nodule should be implemented. 
In other studies, the authors of EU-TI-RADS suggest 
that stiffness on elastography should be considered as 
complementary information in nodule assessment (25), even 
if there is yet no reliable threshold for delineating benign 
from malignant nodules. They also suggest that FNA 
should not be indicated on a nodule if thyroid scintigraphy 
shows this to be warm/hot. 
According to the EU-TI-RADS guidelines, the blood 
flow within the thyroid nodules can be investigated 
with different US imaging modalities, and the type of 
vascularization pattern can be assessed and scored from I to 
III: malignant nodules are usually associated with type III 
vascularization, while benign nodules are usually associated 
with type I and II signal patterns. However, EU-TI-RADS 
emphasizes the fact that vascularity also rises in benign 
nodules and increases in size, while the presence of type 
III vascularization shows low sensitivity, specificity, and 
PPV for malignancy and should be associated with other 
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suspicious US findings (23). Therefore, the reliability of 
Color Doppler in the malignancy assessment of thyroid 
nodules remains controversial: the sensitivity of Doppler 
depends markedly on the US equipment and settings, the 
establishment of central vascularity is highly observer-
dependent, and a quantitative analysis of the Color signals 
is still unclear. Given this, the Color Doppler evaluation 
is not included in the EU-TI-RADS score, but only 
recommended to be used in differentiating solid tissue from 
thick colloid.
In a study to assess the reliability of the first version of 
EU-TI-RADS (26), 430 nodules were examined, and the 
malignancy risks of the EU-TI-RADS categories were 0% 
for TI-RADS 2, 2.2% for TI-RADS 3, 5.9–57.9% for TI-
RADS 4, and 100% for TI-RADS 5.
Recently, Xu et al. (27) observed that the percentage 
of unnecessary FNAs based on EU-TI-RADS was 25.2% 
while another study by Grani et al. (28) reported a EU-TI-
RADS sensitivity of 86.1%, a specificity of 32%, a PPV of 
8.9%, and an NPV of 96.7%.
Korean (K)-TI-RADS
K-TI-RADS was proposed in 2016 by Shin et al. (14). In 
this classification system, the malignancy risk estimated 
by US examination is not determined by a single US sign, 
but by a combination of them; the rationale is that any 
single US predictor is not sensitive and specific enough 
to determine the suspicion of malignancy. Based on US 
patterns including solidity, echogenicity, and suspicious US 
characteristics, thyroid nodules in the K-TI-RADS system 
are classified as high suspicion, intermediate suspicion, low 
suspicion, and benign. 
Evidence  of  microca lc i f ica t ion,  speculated  or 
microlobulated margins, and taller-than-wide shape are 
considered strong predictors of malignancy, with a high 
specificity (>80%), while US appearance of solid internal 
content and hypoechogenicity is considered predictive of 
malignancy, with an intermediate specificity. The decision 
to perform FNA should be based on the calculated risk of 
malignancy according to the US features and nodule size, 
except in case of the presence of poor prognostic factors, 
such as suspected lymph node metastasis, extrathyroidal 
tumour extension, or distant metastasis from thyroid cancer.
It should be noted that nodular vascularization at Color 
Doppler evaluation and elastography appearance are 
described as potentially useful in the distinction between 
benign and malignant nodules, but these are not included 
in the classification as further investigations are needed to 
assess their complementary function in the risk categories. 
According to a study on 2000 nodules (29), FNA criteria 
of K-TI-RADS categories 4 or 5 for nodules ≥1 cm and 
K-TI-RADS 3 for nodules ≥1.5 cm, proved to have a 
sensitivity, specificity, PPV, NPV, and accuracy for overall 
malignancy of 94.5%, 26.8%, 27.5%, 94.3%, and 42.2%, 
respectively (30). K-TI-RADS has also been validated 
by a multicentre prospective study of four institutions 
comprising 902 thyroid nodules, which proved the 
significantly higher malignancy risk of solid hypoechoic 
nodules (73.4%) compared to partially cystic or iso/
hyper echoic nodules (4.3–38.5%; P<0.001); this study 
also demonstrated that the malignancy risk calculated in 
K-TI-RADS categories 5, 4, 3, and 2 were 73.4%, 19.0%, 
3.5%, and 0.0%, respectively; meanwhile, the sensitivity, 
specificity, PPV, NPV, and accuracy of K TI-RADS for 
identification of malignant nodules were 95.5%, 58.6%, 
44.5%, 96.9%, and 69.5%, respectively.
American Association of Clinical 
Endocrinologists (AACE), American College of 
Endocrinology (ACE), and Associazione Medici 
Endocrinologi (AME) classification
AACE/ACE/AME (15) used information provided by US 
examination to stratify nodules into a 3-class system based 
on their risk of malignancy (low, intermediate, and high 
risk) combining US thyroid nodule features and nodule 
dimension with patient clinical history. FNA execution 
is indicated for “high US risk thyroid lesions ≥10 mm”; 
“intermediate US risk thyroid lesions >20 mm”; “low US 
risk thyroid lesions only when >20 mm and increasing 
in size or associated with a risk history and before 
thyroid surgery or minimally invasive ablation therapy”; 
“subcapsular or paratracheal lesions”; “suspicious lymph 
nodes or extra thyroidal spread”; “positive personal or 
family history of thyroid cancer”; and “coexistent suspicious 
clinical findings (e.g., dysphonia)”.
In addition, “nodules with a major diameter <5 mm 
should be monitored, rather than biopsied” and “in nodules 
with a major diameter of 5–10 mm that are associated with 
suspicious US signs, either FNA or watchful waiting may be 
considered”. 
In a prospective study on 987 thyroid nodules 
consecutively referred for FNA, whose aim was determining 
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the diagnostic accuracy of different US classification systems 
and their reliability for FNA indication (31), the AACE/
ACE/AME malignancy rate was 1.1% in low-risk, 4.4% in 
intermediate-risk, and 54.9% in high-risk US categories of 
nodules. The sensitivity, specificity, PPV, NPV, and accuracy 
were 82%, 87%, 54%, 96%, and 86% respectively, with a 
k coefficient of inter-observer agreement of 82%, which 
was higher than those of other classifications. In another 
study including 859 FNAs (32), according to AACE/ACE/
AME guidelines, 341 (39.7%) were low-, 489 (56.9%) 
intermediate-, and 29 (3.4%) were high-risk nodules. Of 
these, 88.5% and 74.9% of low- and intermediate-risk 
nodules, respectively, were cytologically benign, whereas 
84.6% of high-risk nodules had a moderate-to-elevated 
risk of malignancy or were malignant. They suggested that 
the biopsy decision be patient-oriented (considering the 
clinical setting, operator expertise, patient’s preference) 
rather than simply based on nodule size. A further study on 
2,000 nodules with analysis of the diagnostic performance 
of different US guidelines for thyroid nodules (33), AACE/
ACE/AME classification showed a specificity of 80.4%.
Despite this research, the management of nodules with 
intermediate risk at AACE/ACE/AME classification is still 
controversial. Deng et al. (34), in a study on 1,000 patients 
with 1,000 nodules tried to propose a solution with a 
risk stratification system for intermediate-risk nodules of 
AACE/ACE/AME classification, elaborating a predictive 
model: in univariate analysis, they observed that “younger 
patient age, smaller nodule maximum diameter, slight 
hypo-echogenicity, slightly ill-defined margin, no macro-
calcification and indeterminate hyper-echoic spot were 
significantly associated with malignancy” (P<0.05).
With multivariate logistic regression analysis, the authors 
found that indeterminate hyper-echoic spot was the most 
significant independent risk predictor for intermediate risk, 
followed by slightly ill-defined margin, slight hyper-echo, 
and no macro-calcification; the probability of malignancy 
increased with the number of risk factors increasing (34). 
ATA classification
The ATA classification (16) of thyroid nodules is based on 
echostructure, echogenicity, margins, presence/absence of 
microcalcifications, and shape. It provides 5-class scoring 
with a risk for malignancy estimated to each category in 
the following manner: <1% for benign class, <3% for 
very-low suspicion, 5–10% for low suspicion, 10–20% for 
intermediate suspicion, and >70–90% for high suspicion.  
In ATA, classifications completely exclude Color Doppler 
and elastosonography parameters. A previous study on 
1,293 nodules by Yoon et al. (20) considered very-low-
suspicion nodules as negative, and low- to high-suspicion 
nodules as positive. The results demonstrated that ATA 
had a sensitivity of 95.3%, a specificity of 37.4%, a PPV of 
25.2%, an NPV of 97.3%, and an accuracy of 47.9%, with 
a higher specificity, PPV, and accuracy in comparison to 
Kwak’s TI-RADS (P<0.001 for all), albeit a lower specificity 
(P=0.024). In another study (19), ATA showed a sensitivity 
of 98.0%, a specificity of 17.3%, a PPV of 35.0%, and an 
NPV of 95.0%.
In the study by Persichetti et al. (31), ATA achieved a 
sensitivity of 81%, a specificity of 87%, a PPV of 54%, an 
NPV of 96%, and an accuracy of 86%; the interobserver 
agreement was 76.9%.
In the study by Grani et al. (28), the ATA classification 
system achieved a sensitivity of 75%, a specificity of 45.3%, 
a PPV of 9.6%, and an NPV of 95.9%.
In a further study including 112 children totalling 
145 thyroid nodules (31), which compared radiologists’ 
impressions and ATA risk stratification to histology and 
cytology results, the sensitivity in identifying malignancy 
was comparable between ATA guidelines (91%) and the 
radiologists’ impression (90%), while the specificity of the 
radiologists’ malignant impression (80%) was better than 
the ATA guidelines (54%).
Another study by Pandya et al., which examined 1,947 
thyroid nodules (35), was performed to identify the 
limitations of ATA guidelines and demonstrated that PPV 
for cancer increased by ATA category 1 to 5 with measures 
of 0%, 2%, 5%, 12%, and 28%, respectively; this study 
stated that the ATA classification system was optimistic 
about cancer detection rates for the higher-risk nodules and 
that the inter-rater agreement among the 5 readers was fair 
(intraclass correlation coefficient =0.460).
British Thyroid Association (BTA) US 
classification of thyroid nodules
Another existing classification for the US of thyroid nodules 
is that of the BTA (17), which consists of five categories: 
normal (U1), benign (U2), equivocal/indeterminate (U3), 
suspicious (U4), and malignant (U5). It considers the 
following US features as predictors of malignancy: eccentric 
location of the solid portion in partially cystic nodules, non-
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smooth margins, hypoechogenicity of the solid portion, 
microcalcification, and taller-than-wide shape. 
In a study on 104 nodules, with only U2 being 
classified as a negative test and only U5 being classified 
as a positive test, the sensitivity, specificity, positive 
likelihood ratio, negative likelihood ratio, PPV, NPV, and 
accuracy of BTA guidelines were 100%, 91.4%, 11.7%, 
0.0%, 78.6%, 100% and 93.5%, respectively (36). In 
the previously cited study by Chang et al. (19), BTA 
demonstrated a sensitivity of 90%, a specificity of 50.9%, 
a PPV of 45.5%, and an NPV of 91.8%, while in the 
study by Persichetti et al. (31), sensitivity was 74%, 
specificity was 92%, PPV was 62%, NPV was 95%, and 
accuracy was 89%. In a study on 47 patients for correctly 
identifying nodules requiring further investigation, BTA 
guidelines showed a sensitivity of 56%, a specificity of 
81%, a PPV of 81%, and an NPV of 56% (37). 
Comparison between the different US 
classifications for thyroid nodules
It is critical to assess the risk of malignancy in the thyroid 
with US in order to properly identify those patients for 
whom FNA biopsy is a necessary priority. Many studies 
have investigated whether the US characteristics of thyroid 
nodules are useful indicators of histological malignancy. 
Overall, these investigations have identified a few US 
features that are significantly more frequent in malignant 
than in benign thyroid nodules, thus defining a set of US 
features at a higher risk of malignancy. The main features of 
these classifications are summarized on Table 1.
Despite these efforts, none of these classifications 
have been widely adopted worldwide, and there are still 
conflicting recommendations from several different 
societies. However, in the last few years, several studies 
have compared the different US risk stratifications systems 
in large cohorts of patients with thyroid nodules in order 
to evaluate the most accurate and useful system. The major 
results of studies published in the last year are listed below.
In the study of Xu et al., which included a total of 1,460 
benign and 1,005 malignant nodules (27), the distribution 
of malignancies among ACR-TI-RADS levels was 0%, 
2.3%, 7.5%, 40.1%, and 81.4%, respectively. ACR-TI-
RADS showed the best sensitivity (96.6%) in comparison to 
EU-TI-RADS and K-TI-RADS, but the lowest specificity 
(52.9%) and AUC (0.846). K-TI-RADS had good specificity 
(87.4%) but had the lowest (71.4%) sensitivity.
In a study which included two observers and 1,055 
images of thyroid nodules (38), EU-TI-RADS proved to 
have the higher rate of inter-observer agreement in the 
first set of nodules and for indication to perform FNA in 
comparison to the AACE/ACE/AME and ATA guidelines, 
in addition to ACR-TI-RADS and K-TI-RADS.
Middleton et al. (39) evaluated 3,422 thyroid nodules for 
which pathologic findings were available according to the 
ACR-TI-RADS, the K-TI-RADS, and the ATA guidelines. 
The rate of malignant nodules was 89.2% according to 
the ACR-TI-RADS, which was the best performance 
in comparison to the other classification systems. The 
percentage of benign nodules that would be biopsied was 
47.1% for the ACR-TI-RADS, 79.7% for the K-TI-RADS, 
and 78.1% for the ATA guidelines.
In a study including 902 nodules, whose aim was to 
compare the diagnostic performance of ATA guidelines 
with K-TI-RADS and ACR-TI-RADS (40), the calculated 
malignancy risks for nodules of categories 5, 4, 3, 2, and 
1 were 71.7%, 21.5%, 2.6%, 3.8%, and 0%, respectively. 
The ATA guidelines in this study demonstrated significantly 
higher diagnostic sensitivity (95.0%) than the ACR-TI-
RADS (80.2%; P=0.001), but a lower specificity (38.1% 
versus 68.9%; P<0.001); meanwhile, when compared to 
K-TI-RADS, the ATA guidelines showed a lower diagnostic 
sensitivity (100.0%; P=0.07) but a higher specificity (28.2%; 
P<0.001). The unnecessary FNA rate was the lowest 
according to the ACR system (25.8%), followed by the ATA 
(51.2%) and K (59.4%) guidelines.
Finally, in the most recent study on 477 patients (28), 
Grani et al. observed that ACR-TI-RADS proved to be 
the most effective system when compared to other systems 
considered in the analysis (EU-TI-RADS, AACE/ACE/
AME, K-TI-RADS), and allowed for the largest reduction 
of biopsy numbers (268 of 502) with the lowest false 
negative rate of 2.2% (NPV, 97.8%; 95% CI: 95.2–99.2%), 
a sensitivity of 83.3%, a specificity of 56.2%, and a PPV of 
12.8%.
Figures 1-3 summarizes some features of the different US 
classifications.
In conclusion, according to different studies, all US 
malignancy risk stratification systems demonstrated high 
sensitivity and specificity, but unfortunately, the results 
obtained are not yet sufficient to establish the best system. 
Prospective studies and larger cohorts are needed to 
standardize a US classification for application in routine 
clinical practice.
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Table 1 Thyroid nodule scores summary
Classification
US features
Size
ECD 
features
Lymph 
node 
evaluation
Categories
FNA 
recommendationsEchogenicity Shape Margins
Echogenic foci 
(calcification)
TIRADS (11) √ √ √ √ × Included × TI-RADS 1: 
normal thyroid 
gland
FNA recommended 
from TI-RADS 3
TI-RADS 2: 
benign conditions 
TI-RADS 3: 
probably benign 
nodules 
TI-RADS 4: 
suspicious 
nodules 
TI-RADS 5: 
probably 
malignant nodules 
TI-RADS 6: 
malignant nodules
ACR–TIRADS (12) √ √ √ √ √ Included × ACR-TI-RADS 1: 
benign
FNA recommended 
from mildly 
suspicious, 
according on 
nodule size
ACR-TI-RADS 2: 
not suspicious
ACR-TI-RADS 3: 
mildly suspicious
ACR-TI-RADS 
4: moderately 
suspicious
ACR-TI-RADS 5: 
high suspicious
EU-TIRADS (13) √ √ √ √ × Not 
included
√ EU-TI-RADS 1: 
normal 
FNA recommended 
considering US 
scoring + clinical 
setting
EU-TI-RADS 2: 
benign 
EU-TI-RADS 3: 
low risk 
EU-TI-RADS 4: 
intermediate risk
EU-TI-RADS 5: 
high risk
Table 1 (continued)
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Table 1 (continued)
Classification
US features
Size
ECD 
features
Lymph 
node 
evaluation
Categories
FNA 
recommendationsEchogenicity Shape Margins
Echogenic foci 
(calcification)
K-TI-RADS (14) √ √ √ √ √ Not 
included
× K-TI-RADS 1: no 
nodule
FNA 
recommended 
from benign 
lesion, according 
on nodule size 
K-TI-RADS 2: 
benign
K-TI-RADS 3: low 
suspicion
K-TI-RADS 4: 
intermediate 
suspicion
K-TIRADS 5: high 
suspicion
AACE/ACE/ 
AME (15)
√ √ √ √ × Included × 1. Low risk lesion FNA 
recommended 
from low risk 
lesion, according 
on nodule size and 
patient history
2. Intermediate 
risk lesion
3. High risk lesion
ATA (16) √ √ √ √ × Not 
included
× 1. Benign N/A
2. Very low 
suspicion
3. Low suspicion
4. Intermediate 
suspicion
5. High suspicion
BTA (17) √ √ √ √ × Included √ U1: normal N/A
U2: benign
U3: intermediate/
equivocal
U4. suspicious
U5 malignant
TI-RADS, Thyroid Imaging Reporting and Data System; ACR-TI-RADS, American College of Radiologists-TI-RADS; EU-TI-RADS, 
European-TI-RADS; K-TI-RADS, Korean-TI-RADS; AACE/ACE/AME, American Association of Clinical Endocrinologists/American College 
of Endocrinology/Associazione Medici Endocrinologi; ATA, American Thyroid Association; BTA, British Thyroid Association.
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Figure 1 Transverse ultrasonography shows an isoechoic and hyperechoic mixed solid-cystic nodule with well-defined margins (arrowheads). In 
AACE/ACE/AME classification, this nodule is grade 1 (low-risk lesion); in TI-RADS by Horvath, the lesion is Colloid Type 1 (TI-RADS 2); in TI-
RADS by Kwak, it is TI-RADS 3 (not suspicious US features); in ACR-TI-RADS, it is TR 2 (not suspicious); in ATA classification, it is a nodule 
with low suspicion of malignancy; in EU-TI-RADS, it is grade 3 (low risk); in K-TI-RADS, it is a lesion with low suspicion of malignancy; in BTA 
classification, the lesion is grade U2 (benign). According to the US classifications, the patient did not undergo to fine-needle biopsy. AACE, American 
Association of Clinical Endocrinologists; ACE, American College of Endocrinology; AME, Associazione Medici Endocrinologi; TI-RADS, Thyroid 
Imaging Reporting and Data System; ACR-TI-RADS, American College of Radiology (ACR)-TI-RADS; EU-TI-RADS, European (EU)-TI-RADS; 
K-TI-RADS, Korean (K)-TI-RADS; BTA, British Thyroid Association; ATA, American Thyroid Association; US, ultrasound. 
Figure 2 A longitudinal ultrasonography image shows a single, iso-hypoechoic, thyroid nodule with regular hypoechoic margins (arrowheads) 
and a taller-than-wide shape. In AACE/ACE/AME classification, this nodule is grade 2 (intermediate risk lesion); in TI-RADS, it is TI-
RADS 4a (undetermined); in TI-RADS by Kwak, it is TI-RADS 4b (2 suspicious US features); in ACR-TI-RADS, it is TR 4 (moderately 
suspicious); in ATA classification, the nodule has intermediate suspicion of malignancy; in EU-TI-RADS, it is grade 4 (intermediate risk); 
in K-TI-RADS, it is a nodule with intermediate suspicion of malignancy; in BTA classification, it is grade U3 (intermediate/equivocal). The 
fine-needle aspiration cytology confirmed a benign nodule. AACE, American Association of Clinical Endocrinologists; ACE, American 
College of Endocrinology; AME, Associazione Medici Endocrinologi; TI-RADS, Thyroid Imaging Reporting and Data System; ACR-TI-
RADS, American College of Radiology (ACR)-TI-RADS; EU-TI-RADS, European (EU)-TI-RADS; K-TI-RADS, Korean (K)-TI-RADS; 
BTA, British Thyroid Association; ATA, American Thyroid Association; US, ultrasound.
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